Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical uses of non-nucleoside reverse transcriptase inhibitors

1 Jan 2000

Abstract excerpt

Three non-nucleoside reverse transcriptase inhibitors (NNRTIs) are currently available for treatment of HIV-1 as part of combination antiretroviral therapy. Oral dosing is administered three times daily for delavirdine (DLV), twice daily for nevirapine (NVP), and once daily for efavirenz (EFV). Rash is a common side effect of all three NNRTIs, and early CNS side effects are also frequent with EFV. Hepatotoxicity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV-related health complications and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10891870
DOI: 10.1002/1099-1654(200007/08)10:4<217::aid-rmv279>3.0.co;2-l

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical uses of non-nucleoside reverse transcriptase inhibitorsPMID 10891870Read ↗

Non-nucleoside reverse transcriptase inhibitors: a reviewSemantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)Semantic proximity Read ↗

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsSemantic proximity Read ↗

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentSemantic proximity Read ↗

Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse TranscriptaseSemantic proximity Read ↗

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read ↗

Nonnucleoside Reverse Transcriptase Inhibitor ResistanceSemantic proximity Read ↗

New nucleoside reverse transcriptase inhibitors for the treatment of HIV infectionsSemantic proximity Read ↗

Nonnucleoside Reverse Transcriptase Inhibitor ResistanceSemantic proximity Read ↗

Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.Semantic proximity Read ↗

Emivirine: an NRTI that functions as an NNRTI.Semantic proximity Read ↗

Adverse effects of reverse transcriptase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.